Implementación clínica del cociente sFlt-1/PlGF como herramienta diagnóstica y pronóstica de la preeclampsia y la restricción del crecimiento intrauterino

Laburpena

Preeclampsia (PE) is a gestational hypertensive disorder characterized by a systemic vascular maternal disease. It affects 2-8% of pregnancies, and is the second cause of obstetric mortality, being involved in 15% of maternal deaths, which means more than 50,000 cases per year (1, 2). Fetal growth restriction (FGR) refers to a situation where the fetus does not reach his full growth potential. It affects 3-5% of pregnancies and is related to an increased neonatal morbimortality and other comorbidities during infant and adulthood (3). Both PE and FGR are included in the same spectrum of pregnancy complications derived from placental dysfunction, and are associated to higher maternal and fetal morbimortality, especially when leading to a preterm delivery. Thus, they both share risk factors, and often appear simultaneously, this increasing adverse outcomes (4). Accurate and early diagnosis, as well as the optimization of perinatal care, are of capital importance for the reduction of their potential complications...